Product logins

Find logins to all Clarivate products below.


Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., J&J Innovative Medicine’s Akeega, Pfizer’s talazoparib) and radioligand therapies (Novartis’s Pluvicto), and anticipated approvals of emerging therapies (e.g., AstraZeneca’s saruparib and Merck’s opevesostat), will drive robust market growth over the 2024-2034 forecast period.

Questions answered

  • What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
  • How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?
  • What are interviewed experts’ insights on the current treatment options for prostate cancer?· How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radionuclide therapies, reshape the prostate cancer treatment landscape?
  • What is the clinical and commercial potential of emerging regimens, like opevesostat and saruparib? How are they likely to be positioned in the market?

Geography: United States, EU5, Japan

Primary research: 18 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Incidence of prostate cancer by country, segmented by risk of biochemical recurrence and TNM staging; market-relevant drug-treatable and drug-treated populations

Forecast: 10-year, annualized, drug-level sales and patient share of key prostate cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…